BioCentury | Apr 25, 2011
Finance

Third Deal on the Run

...as well as new investor Arch Venture Partners. bluebird, which until September was known as Genetix Pharmaceuticals Inc....
BioCentury | Apr 21, 2011
Financial News

bluebird raises $30 million

...in Phase I/II testing for sickle cell anemia and beta thalassemia. bluebird was formerly named Genetix Pharmaceuticals Inc. BC...
BioCentury | Sep 20, 2010
Company News

bluebird bio management update

...Hematology, Neurology Transitioned: Nick Leschly to president and CEO from interim president of bluebird (formerly Genetix Pharmaceuticals Inc....
BioCentury | Sep 20, 2010
Clinical News

LentiGlobin gene therapy: Phase I/II data

...bluebird bio (formerly Genetix Pharmaceuticals Inc. ) and colleagues reported data from the first patient treated with its...
BioCentury | Sep 16, 2010
Clinical News

bluebird publishes LentiGlobin data for beta thalassemia

...into a patient's own hematopoietic stem cells in the bone marrow. bluebird was formerly named Genetix Pharmaceuticals Inc. BC...
BioCentury | Jun 7, 2010
Clinical News

Lenti-D gene therapy: Additional Phase I data

...published data on 2 patients at 24-30 months of follow-up (see BioCentury, Nov. 23, 2009). Genetix Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Finance

Easton's "OAD" Model

...rounds for two existing investments: ophthalmic and renal company Promedior Inc. and gene therapy company Genetix Pharmaceuticals Inc. BC...
BioCentury | Mar 15, 2010
Finance

Ebb & Flow

...therapy will finally work. Third Rock Ventures led a $35 million series B round for Genetix Pharmaceuticals Inc....
BioCentury | Mar 15, 2010
Company News

Genetix board of directors update

Genetix Pharmaceuticals Inc. , Cambridge, Mass. Business: Gene/Cell therapy, Cancer, Cardiovascular Appointed: Jim Geraghty, SVP at Genzyme Corp. ; Nick Leschly, partner at Third Rock Ventures; Geert-Jan Mulder, general partner at Forbion; and Axel Polack, general...
BioCentury | Mar 15, 2010
Company News

Genetix management update

Genetix Pharmaceuticals Inc. , Cambridge, Mass. Business: Gene/Cell therapy, Cancer, Cardiovascular Hired: Mitchell Finer as CSO, formerly SVP of product development at Novocell Inc. ; Nick Leschly, partner at Third Rock Ventures, as interim president; and...
Items per page:
1 - 10 of 30
BioCentury | Apr 25, 2011
Finance

Third Deal on the Run

...as well as new investor Arch Venture Partners. bluebird, which until September was known as Genetix Pharmaceuticals Inc....
BioCentury | Apr 21, 2011
Financial News

bluebird raises $30 million

...in Phase I/II testing for sickle cell anemia and beta thalassemia. bluebird was formerly named Genetix Pharmaceuticals Inc. BC...
BioCentury | Sep 20, 2010
Company News

bluebird bio management update

...Hematology, Neurology Transitioned: Nick Leschly to president and CEO from interim president of bluebird (formerly Genetix Pharmaceuticals Inc....
BioCentury | Sep 20, 2010
Clinical News

LentiGlobin gene therapy: Phase I/II data

...bluebird bio (formerly Genetix Pharmaceuticals Inc. ) and colleagues reported data from the first patient treated with its...
BioCentury | Sep 16, 2010
Clinical News

bluebird publishes LentiGlobin data for beta thalassemia

...into a patient's own hematopoietic stem cells in the bone marrow. bluebird was formerly named Genetix Pharmaceuticals Inc. BC...
BioCentury | Jun 7, 2010
Clinical News

Lenti-D gene therapy: Additional Phase I data

...published data on 2 patients at 24-30 months of follow-up (see BioCentury, Nov. 23, 2009). Genetix Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Finance

Easton's "OAD" Model

...rounds for two existing investments: ophthalmic and renal company Promedior Inc. and gene therapy company Genetix Pharmaceuticals Inc. BC...
BioCentury | Mar 15, 2010
Finance

Ebb & Flow

...therapy will finally work. Third Rock Ventures led a $35 million series B round for Genetix Pharmaceuticals Inc....
BioCentury | Mar 15, 2010
Company News

Genetix board of directors update

Genetix Pharmaceuticals Inc. , Cambridge, Mass. Business: Gene/Cell therapy, Cancer, Cardiovascular Appointed: Jim Geraghty, SVP at Genzyme Corp. ; Nick Leschly, partner at Third Rock Ventures; Geert-Jan Mulder, general partner at Forbion; and Axel Polack, general...
BioCentury | Mar 15, 2010
Company News

Genetix management update

Genetix Pharmaceuticals Inc. , Cambridge, Mass. Business: Gene/Cell therapy, Cancer, Cardiovascular Hired: Mitchell Finer as CSO, formerly SVP of product development at Novocell Inc. ; Nick Leschly, partner at Third Rock Ventures, as interim president; and...
Items per page:
1 - 10 of 30